Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is Rosalind Advisors Inc.’s 7th Largest Position

Rosalind Advisors Inc. reduced its stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 0.5% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 3,104,995 shares of the company’s stock after selling 15,175 shares during the period. Xeris Biopharma makes up 5.6% of Rosalind Advisors Inc.’s holdings, making the stock its 7th biggest holding. Rosalind Advisors Inc.’s holdings in Xeris Biopharma were worth $8,849,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. boosted its stake in Xeris Biopharma by 64.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 28,657 shares of the company’s stock valued at $82,000 after acquiring an additional 11,239 shares during the last quarter. Goldstein Advisors LLC lifted its position in shares of Xeris Biopharma by 19.7% during the third quarter. Goldstein Advisors LLC now owns 30,425 shares of the company’s stock worth $87,000 after purchasing an additional 5,000 shares during the last quarter. Wealth Enhancement Advisory Services LLC bought a new position in shares of Xeris Biopharma during the third quarter worth about $35,000. CWM LLC grew its stake in Xeris Biopharma by 93.7% in the third quarter. CWM LLC now owns 34,167 shares of the company’s stock worth $97,000 after purchasing an additional 16,530 shares in the last quarter. Finally, SG Americas Securities LLC increased its holdings in Xeris Biopharma by 188.5% in the third quarter. SG Americas Securities LLC now owns 60,202 shares of the company’s stock valued at $172,000 after buying an additional 39,335 shares during the last quarter. 42.75% of the stock is owned by institutional investors and hedge funds.

Xeris Biopharma Price Performance

XERS stock opened at $3.26 on Wednesday. The firm has a market cap of $485.74 million, a price-to-earnings ratio of -7.58 and a beta of 2.70. Xeris Biopharma Holdings, Inc. has a 1-year low of $1.46 and a 1-year high of $3.39. The firm has a fifty day moving average price of $2.92 and a two-hundred day moving average price of $2.46.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.01. Xeris Biopharma had a negative net margin of 32.83% and a negative return on equity of 16,662.63%. The firm had revenue of $48.07 million for the quarter, compared to analyst estimates of $46.80 million. During the same quarter in the prior year, the business earned ($0.14) earnings per share. As a group, analysts expect that Xeris Biopharma Holdings, Inc. will post -0.4 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $6.00 target price on shares of Xeris Biopharma in a report on Thursday, August 15th.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.